1. Home
  2. Live Updates
  3. Clin urol

Live Breaking News & Updates on Clin urol

Stay informed with the latest breaking news from Clin urol on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Clin urol and stay connected to the pulse of your community

TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non-muscle-invasive bladder cancer

/PRNewswire/ -- Johnson & Johnson announced today updated results from Cohort 2 of the Phase 2b SunRISe-1 study evaluating the efficacy and safety of...

United-kingdom , United-states , Texas , San-antonio , American , Ania-diantonio , Indianj-urol , Joseph-jacob , Prnewswire-johnson , Clin-urol , Janssen-research-development , American-cancer-society

TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non-muscle-invasive bladder cancer

TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non-muscle-invasive bladder cancer
bubblear.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bubblear.com Daily Mail and Mail on Sunday newspapers.

San-antonio , Texas , United-states , United-kingdom , American , Joseph-jacob , Clin-urol , Indianj-urol , Ania-diantonio , Department-of-urology , European-association-of-urology , European-society-for-medical-oncology

Johnson & Johnson's Investigational TAR-200 Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer

/PRNewswire/ -- Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted TAR-200 Breakthrough Therapy Designation (BTD)...

United-states , United-kingdom , American , Brian-kenney , Clin-urol , Kiran-patel , Indianj-urol , Prnewswire-johnson , Johnson , Exchange-commission , Janssen-biotech-inc , Drug-administration

Johnson & Johnson : Results from Phase 2 THOR-2 Study Show Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor -October 23, 2023 at 07:22 am EDT

News Release


Media Contacts:


Suzanne Frost


+1 416-317-0304


Brian Kenney +1 215-620-0111

...

United-kingdom , Madrid , Spain , James-wf-catto , Indianj-urol , Clin-urol , Brian-kenney , Kiran-patel , Jnjinnovmedand-janssen , Exchange-commission , Drug-administration , Johnson

TAR-200 Intravesical Delivery System Results Show 77 Percent Complete Response Rate in Patients with Bacillus-Calmette-Guérin Unresponsive, High-Risk Non-Muscle-Invasive Bladder Cancer

Phase 2b SunRISe-1 study results showed sustained, durable complete responses beyond one year with intravesical gemcitabine delivery system MADRID, Oct. 22, 2023 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that data from the Phase 2b SunRISe-1 study evaluating the efficacy and safety of TAR-200 monotherapy in patients with Bacillus Calmette-Guérin (BCG)-unresponsive, […]

Spain , United-kingdom , Italy , United-states , Madrid , American , Brian-kenney , Clin-urol , Andrea-necchi , Scientific-institute , None-of-janssen-research-development , Janssen-research-development

Results from Phase 2 THOR-2 Study Show Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations Treated with BALVERSA® (erdafitinib) Versus Chemotherapy

Data from Cohort 1 of the Phase 2 THOR-2 study showed oral erdafitinib reduced the risk of disease recurrence or death compared with intravesical standard-of-care chemotherapy MADRID, Oct. 21, 2023 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 2 randomized, open-label THOR-2 study evaluating BALVERSA® versus investigator […]

Madrid , Spain , United-kingdom , Clin-urol , Brian-kenney , Indianj-urol , Kiran-patel , James-wf-catto , Janssen-research-development , Janssen-biotech-inc , University-of-sheffield , European-society-for-medical-oncology-congress

Results from Phase 2 THOR-2 Study Show Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alteration

Results from Phase 2 THOR-2 Study Show Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alteration
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Spain , Madrid , United-kingdom , Brian-kenney , James-wf-catto , Indianj-urol , Kiran-patel , Clin-urol , Astex-pharmaceuticals , Janssen-pharmaceutical-companies-of-johnson , Companies-of-johnson , Janssen-biotech-inc